Effectiveness of Informational and Educational Tools to Improve the Experience of Relatives of ICU Patients. RELIEF, a Platform Trial

NCT ID: NCT06851884

Last Updated: 2025-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

562 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-01

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The admission of a patient to an intensive care unit (ICU) is associated with high levels of acute stress, anxiety, and depression among relatives, as well as extreme emotions such as fear, guilt, distress, and helplessness. In addition to these emotions, relatives also struggle to understand the information provided by the medical team-only half of the information is fully understood. These emotional and cognitive difficulties can become obstacles in decision-making processes and may have medium- and long-term consequences on their psychological well-being, particularly in terms of post-traumatic stress disorder (PTSD), anxiety, and depression. Three months after the patient is discharged from the ICU, one-third of relatives exhibit symptoms of PTSD.

The aim of this research is to propose a variety of informational and educational tools to improve relatives' understanding of both the ICU context and the information provided, with the goal of reducing the risk of developing PTSD in the months following the patient's discharge or death.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Traumatic Stress Disorder PTSD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized platform trial designed to investigate a clinical question across multiple subpopulations and involving multiple interventions.

The trials integrated into the platform trial are randomized and may be either conventional trials or adaptive MAMS (Multi-Arms Multi-Stage) trials. These involve multiple arms and phases, allowing for the adaptive evaluation of several interventions, with the possibility of adding or removing interventions during the trial.

Additionally, the trials include a hybrid control arm that combines randomized concurrent controls and historical external controls from an observational cohort.

Trial 1 : randomization according to a 1:2:2:2 ratio into one of the 4 arms:

* Control
* Video capsules
* Comic strips
* Virtual reality

Trial 2 : randomization according to a 1:2 ratio into the control or intervention arm (set of "end-of-life and grief" informational and educational tools, including a video capsule, a cartoon, and a kit of 2 leaflets).
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Trial 1 : Control

Standard care with universal welcome leaflet. The control group is a hybrid, also including historical external controls from the cohort "Syndrome de Stress Post-traumatique chez les Proches de Patients Admitted to the Intensive Care Unit: A Multicentric, Observational, Prospective Study" according to the center's usual practice

Group Type ACTIVE_COMPARATOR

Standard of Care (SOC)

Intervention Type OTHER

Universal welcome leaflet on patient admission

Trial 1 : Video Capsule arm

Group Type EXPERIMENTAL

Video capsules

Intervention Type OTHER

3 video capsules of 3 minutes each

Trial 1 : Cartoon arm

Group Type EXPERIMENTAL

Cartoon

Intervention Type OTHER

3 cartoons

Trial 1 : Virtual reality arm

Group Type EXPERIMENTAL

Virtual reality

Intervention Type OTHER

3 virtual reality programs

Trial 2 : Control

Standard care with universal welcome leaflet. The control group is a hybrid, also including historical external controls from the cohort "Syndrome de Stress Post-traumatique chez les Proches de Patients Admitted to the Intensive Care Unit: A Multicentric, Observational, Prospective Study" according to the center's usual practice

Group Type ACTIVE_COMPARATOR

Standard of Care (SOC)

Intervention Type OTHER

Universal welcome leaflet on patient admission

Trial 2 : set of "end-of-life and grief" informational and educational tools

Group Type EXPERIMENTAL

Set of "end-of-life and grief" informational and educational tools

Intervention Type OTHER

Including a video capsule, a cartoon, and a kit of two leaflets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard of Care (SOC)

Universal welcome leaflet on patient admission

Intervention Type OTHER

Video capsules

3 video capsules of 3 minutes each

Intervention Type OTHER

Cartoon

3 cartoons

Intervention Type OTHER

Virtual reality

3 virtual reality programs

Intervention Type OTHER

Set of "end-of-life and grief" informational and educational tools

Including a video capsule, a cartoon, and a kit of two leaflets

Intervention Type OTHER

Standard of Care (SOC)

Universal welcome leaflet on patient admission

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Trial 1 :

Relatives of patients with the following characteristics: ≥18 years old, treated in intensive care with invasive mechanical ventilation for at least 48 hours having received a visit from at least one relative within the first 72 hours.

* ≥18 years old
* Identified, if possible, by the patient as the reference person or person to be informed, or, if the patient is unable to communicate, identified by the healthcare providers as the "patient's reference relative."
* Understanding and speaking French • Having provided their phone contact information Only one relative of the patient is included in the study.

Trial 2 :

Relatives of patients with the following characteristics: ≥18 years old, having been treated in intensive care with invasive mechanical ventilation for at least 48 hours, for whom a decision of withhold or withdraw treatment has been made with expected death in intensive care.

* ≥18 years old
* Identified, if possible, by the patient as the reference person or person to be informed, or, if the patient is unable to communicate, identified by healthcare providers as the "patient's reference relative."
* Present at the end-of-life conference (announcement of the EOL decision)
* Understanding and speaking French
* Having provided their phone contact information

Only one relative of the patient is included in the study. They are included just before or just after the end-of-life conference.

Exclusion Criteria

Patients :

* Planned or considered organ donation
* Detained or deprived of liberty
* Under guardianship or curatorship
* No social security

Relatives :

* Social context making follow-up and telephone interviews difficult (homeless individuals, not residing in Europe or the overseas territories)
* Inability to provide a "stable" personal mobile number (temporary phone number or not in their own name or the name of their spouse/partner)
* Under guardianship or curatorship
* Inability to communicate by phone (hearing impairments, etc.)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nancy Kentish-Barnes, MD

Role: CONTACT

+33142499421 ext. +33

Jérôme Lambert, MD PhD

Role: CONTACT

+33142499742

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP240666

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ICU-VR Prior to ICU Admission
NCT06642636 RECRUITING NA